Real-world experience with intravitreal pegcetacoplan for the treatment of GA

News
Article

This retrospective real-world evaluation of the drug considered a number of important as-yet-unanswered questions.

Image credit: AdobeStock/AIExplosion

(Image credit: AdobeStock/AIExplosion)

Reviewed by Philip J. Rosenfeld, MD, PhD

Philip J. Rosenfeld, MD, PhD, Professor of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, reported the real-world performance of pegcetacoplan (Syfovre, Apellis Pharmaceuticals) in patients with geography atrophy (GA) at the Clinical Trials at the Summit 2024 annual meeting on June 8, in Park City, Utah. A top-line finding was that pegcetacoplan reduced the annualized growth rate of GA by about 41% over 9 months of therapy.

This retrospective real-world evaluation of the drug considered a number of important as-yet-unanswered questions, such as determination of the best patients to treat, the response to pegcetacoplan by eyes with macular atrophy previously treated with anti-vascular endothelial growth factor (VEGF) drugs, the response to pegcetacoplan by non-exudative macular neovascularization (MNV) at baseline, and if all pegcetacoplan-associated exudation was related to MNV and if anti-VEGF therapy is required.

Retrospective analysis

All included eyes (135 eyes of 105 patients treated from 4/12/2023 to 4/23/2024, 962 injections) had symptomatic GA secondary to age-related macular degeneration (AMD) that had initially been treated monthly with 15 mg of intravitreal pegcetacoplan. Swept-source optical coherence tomography angiography (OCTA) measured the GA lesion sizes and determined the presence of non-exudative MNV, and onset and progression of exudation. The growth rate of GA and the best-corrected visual acuity (BCVA) were assessed at 6 and 9 months, Rosenfeld recounted.

The mean baseline patient age was 81 ± 8 years, of whom 72% were women. The mean BCVA at baseline (Early Treatment Diabetic Retinopathy Study equivalent letters) in the study and fellow eyes, respectively, were 63 ± 13 letters (~Snellen: 20/60) and 52 ± 25 letters (~Snellen 20/100). Twelve eyes (10 patients) had been treated previously with anti-VEGF therapy; 9 eyes (9 patients) had non-exudative MNV at baseline.

6-month GA growth rate

In the 101 eyes (75 patients) with a minimal 6-month follow-up, the square-root GA growth rate after pegcetacoplan treatment was 0.24 ± 0.15 mm/year; in 63 eyes with prior annual visits, the respective square-root GA growth rates before and after pegcetacoplan were 0.33 ± 0.22 mm/year and 0.20 ± 0.12 mm/year. Rosenfeld reported that the growth rate decreased by 39% (p<0.001).

9-month GA growth rate

In 74 eyes (58 patients) with a minimal 9-month follow-up, the square-root GA growth rate after pegcetacoplan treatment was 0.21 ± 0.13 mm/year. In the 49 eyes with prior annual visits, the respective square-root GA growth rates before and after pegcetacoplan were 0.32 ± 0.22 mm/year and 0.19 ± 0.11 mm/year. Rosenfeld reported that the growth rate decreased by 41% (p<0.001).

Real-world observations

Exudation seemed to be the major side effect of pegcetacplan and developed in 23% of all 101 eyes following an average of 6 injections.

Regarding safety, vitritis developed in 1 eye (1%); steroid treatmentresulted in a BCVA return to baseline.

Disc edema developed in 3 eyes (3%), the BCVA remained stable, and pegcetacoplan therapy was continued.

No cases of infectious or non-infectious endophthalmitis or occlusive vasculitis developed.

Take-Home Messages

  • Pegcetacoplan effectively reduced the annualized growth rate of GA by about 41% at 9 months.
  • Exudation associated with pegcetacoplan developed in 23 eyes (23%) over a mean period of 9 months, but only 11 eyes (11%) required anti-VEGF therapy.
  • Most exudation was not due to MNV as documented by swept-source OCTA.
  • OCT macular thickness maps were useful for managing patients with pegcetacoplan-related exudation

Phillip J. Rosenfeld, MD, PhD

E: prosenfeld@med.miami.edu

Rosenfeld is Professor of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami.He has a financial interest in this subject matter. Rosenfeld is an advisor for Apellis and holds equity in Apellis.

Presentation
Rosenfeld PJ. Real-World Experience with Intravitreal Pegcetacoplan for the Treatment of GA. Presented at the Clinical Trials 2024 at the Summit; June 9, Park City, Utah. Session: First-Time Results of Clinical Trials

Newsletter

Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.

Recent Videos
Abby Markward and Hattie Hayes discuss the ASCRS Annual Meeting, the ASOA Annual Meeting, and the Retina Day event.
WIO 2024: An educator's perspective on shattering glass ceilings in ophthalmology
Hannah Chiu, MD, FRCSC, highlights some of the early benefits of an AI-operated telephone call system for postoperative patient care at WIO 2024
Retinal Inner Layer Disorganization and OCT in Uveitic Macular Edema: Insights from Dr. Amitha Domalpally
ARVO 2024: Study Reveals Faricimab's Potential for Extended Dosing in nAMD
© 2025 MJH Life Sciences

All rights reserved.